| Application no. and date | 17800976.7 (espacenet) (Federated) (European Patent Register), 20171018 | | Patent/reg. no. and date | DK/EP 3529360, 20240417 | | Publication date | 20190828 | | Priority no. and date | US 201662409816 P, 20161018, US 201662422028 P, 20161114, US 201762472525 P, 20170316, US 201762550426 P, 20170825 | | EP pub. no. and date |
EP 3529360 20190828 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | 170007/BT/SD | | Inventor | WIJNGAARD, Peter, Livingston
New Jersey 07039 USA
c/o The Medicines Company
8 Sylvan Way
Parsippany
NJ 07054, US,
KALLEND, David, Wollerau
Kanton Schwyz
88321 Switzerland
c/o The Medicines Company
8 Sylvan Way
Parsippany
NJ 07054, US | | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | | Opponent | | | IPC Class | A61K 31/713 (2006.01) , C12N 15/113 (2010.01) | | Title | FREMGANGSMÅDER TIL FOREBYGGELSE AF KARDIOVASKULÆRE HÆNDELSER VED REDUCERING AF PROTEINET PROPROTEIN-KONVERTASE-SUBTILISIN-KEXIN 9 (PCSK9) | | Int. application no. | US2017057218 | | Int. publication no. | WO2018075658 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
